Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 May;21(5):515–520. doi: 10.1111/j.1365-2125.1986.tb02834.x

Cimetidine absorption in humans during sucralfate coadministration.

R D'Angio, M Mayersohn, K A Conrad, M Bliss
PMCID: PMC1401033  PMID: 3755052

Abstract

Cimetidine absorption after a single 300 mg oral dose was evaluated in six normal subjects in the absence or presence of sucralfate. Sucralfate was ingested four times a day for 2 days prior to and for two additional doses on the day of cimetidine ingestion. Sucralfate coadministration had no statistically significant influence on the rate or extent of cimetidine absorption.

Full text

PDF
515

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodemar G., Norlander B., Walan A. Diminished absorption of cimetidine caused by antacids. Lancet. 1979 Feb 24;1(8113):444–445. doi: 10.1016/s0140-6736(79)90924-3. [DOI] [PubMed] [Google Scholar]
  2. Borella L. E., Seethaler K., Lippmann W. Sucralfate: antipeptic, antiulcer activities and antagonism of gastric emptying. Arzneimittelforschung. 1979;29(5):793–798. [PubMed] [Google Scholar]
  3. Burland W. L., Darkin D. W., Mills M. W. Effect of antacids on absorption of cimetidine. Lancet. 1976 Oct 30;2(7992):965–965. doi: 10.1016/s0140-6736(76)90933-8. [DOI] [PubMed] [Google Scholar]
  4. Freston J. W. Cimetidine. I. Developments, pharmacology, and efficacy. Ann Intern Med. 1982 Oct;97(4):573–580. doi: 10.7326/0003-4819-97-4-573. [DOI] [PubMed] [Google Scholar]
  5. Grahnén A., von Bahr C., Lindström B., Rosén A. Bioavailability and pharmacokinetics of cimetidine. Eur J Clin Pharmacol. 1979 Nov;16(5):335–340. doi: 10.1007/BF00605632. [DOI] [PubMed] [Google Scholar]
  6. Gugler R., Brand M., Somogyi A. Impaired cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharmacol. 1981;20(3):225–228. doi: 10.1007/BF00544602. [DOI] [PubMed] [Google Scholar]
  7. Gugler R., Fuchs G., Dieckmann M., Somogyi A. A. Cimetidine plasma concentration-response relationships. Clin Pharmacol Ther. 1981 Jun;29(6):744–748. doi: 10.1038/clpt.1981.105. [DOI] [PubMed] [Google Scholar]
  8. Henn R. M., Isenberg J. I., Maxwell V., Sturdevant R. A. Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer. N Engl J Med. 1975 Aug 21;293(8):371–375. doi: 10.1056/NEJM197508212930802. [DOI] [PubMed] [Google Scholar]
  9. Lam F. C., Hung C. T., Perrier D. G. Estimation of variance for harmonic mean half-lives. J Pharm Sci. 1985 Feb;74(2):229–231. doi: 10.1002/jps.2600740229. [DOI] [PubMed] [Google Scholar]
  10. Mihaly G. W., Cockbain S., Jones D. B., Hanson R. G., Smallwood R. A. High-pressure liquid chromatographic determination of cimetidine in plasma and urine. J Pharm Sci. 1982 May;71(5):590–592. doi: 10.1002/jps.2600710528. [DOI] [PubMed] [Google Scholar]
  11. Mungall D., Talbert R. L., Phillips C., Jaffe D., Ludden T. M. Sucralfate and warfarin. Ann Intern Med. 1983 Apr;98(4):557–557. doi: 10.7326/0003-4819-98-4-557_2. [DOI] [PubMed] [Google Scholar]
  12. Nagashima R. Development and characteristics of sucralfate. J Clin Gastroenterol. 1981;3(Suppl 2):103–110. [PubMed] [Google Scholar]
  13. Nagashima R., Hirano T. Selective binding of sucralfate to ulcer lesion. I. Experiments in rats with acetic acid-induced gastric ulcer receiving unlabelled sucralfate. Arzneimittelforschung. 1980;30(1):80–83. [PubMed] [Google Scholar]
  14. Pancorbo S., Bubrick M. P., Chin T. W., Miller K. W., Onstad G. Cimetidine dynamics after single intravenous doses. Clin Pharmacol Ther. 1982 Jan;31(1):83–88. doi: 10.1038/clpt.1982.13. [DOI] [PubMed] [Google Scholar]
  15. Pedersen P. V., Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci. 1980 Apr;69(4):394–398. doi: 10.1002/jps.2600690408. [DOI] [PubMed] [Google Scholar]
  16. Pounder R. E., Williams J. G., Russell R. C., Milton-Thompson G. J., Misiewicz J. J. Inhibition of food-stimulated gastric acid secretion by cimetidine. Gut. 1976 Mar;17(3):161–168. doi: 10.1136/gut.17.3.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ritschel W. A., Banerjee P. S., Koch H. P., Czeijka M. Cimetidine-sucralfate drug interaction. Methods Find Exp Clin Pharmacol. 1984 May;6(5):261–263. [PubMed] [Google Scholar]
  18. Steinberg W. M., Lewis J. H., Katz D. M. Antacids inhibit absorption of cimetidine. N Engl J Med. 1982 Aug 12;307(7):400–404. doi: 10.1056/NEJM198208123070703. [DOI] [PubMed] [Google Scholar]
  19. Steiner K., Bühring K. U., Faro H. P., Garbe A., Nowak H. Sucralfate: pharmacokinetics, metabolism and selective binding to experimental gastric and duodenal ulcers in animals. Arzneimittelforschung. 1982;32(5):512–518. [PubMed] [Google Scholar]
  20. Walkenstein S. S., Dubb J. W., Randolph W. C., Westlake W. J., Stote R. M., Intoccia A. P. Bioavailability of cimetidine in man. Gastroenterology. 1978 Feb;74(2 Pt 2):360–365. [PubMed] [Google Scholar]
  21. Yoshida N., Terao N., Nagashima R. Sucralfate, a basic aluminum salt of sucrose sulfate. IV. Interaction with enzyme pepsin. Arzneimittelforschung. 1980;30(1):78–80. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES